<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01044446</url>
  </required_header>
  <id_info>
    <org_study_id>CRE-2009.481</org_study_id>
    <nct_id>NCT01044446</nct_id>
  </id_info>
  <brief_title>Effect of Icodextrin on the Treatment Outcome of Peritoneal Dialysis Patients During Acute Peritonitis</brief_title>
  <official_title>Effect of Icodextrin on the Treatment Outcome of Peritoneal Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the present study is to evaluate the a prior hypothesis that treatment with
      icodextrin during acute peritonitis would improve the treatment outcomes of peritonitis
      complicating peritoneal dialysis. The safety and effectiveness of icodextrin for decreasing
      glucose exposure, extent and severity of peritonitis will be evaluated in the setting of
      acute peritonitis complicating peritoneal dialysis among patients who are not receiving
      icodextrin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>peritoneal dialysate total white cell count on day 3 of acute peritonitis</measure>
    <time_frame>day 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>need of additional hypertonic exchanges, ultrafiltration volumes according to patient diary, fluid control as denoted by changes in body weight, and the timing of peritonitis resolution</measure>
    <time_frame>within the period of peritonitis treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Peritonitis</condition>
  <arm_group>
    <arm_group_label>Icodextrin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>peritoneal dialysate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucose-based dialysate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>peritoneal dialysate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Icodextrin</intervention_name>
    <description>one exchange daily</description>
    <arm_group_label>Icodextrin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glucose-based peritoneal dialysate</intervention_name>
    <description>original exchange frequency</description>
    <arm_group_label>Glucose-based dialysate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged 18 or older on peritoneal dialysis, who develop clinical evidence of peritonitis

          -  stable peritoneal dialysis with Baxter connection system

          -  willingness to give written consent and comply with the study protocol

        Exclusion Criteria:

          -  already on icodextrin dialysate prior to acute presentation with peritonitis

          -  known allergy or hypersensitivity to icodextrin, starch or have a glycogen storage
             disease

          -  participation in another interventional study within last 30 days of randomization

          -  history of a psychological illness or condition that would interfere with the
             patient's ability to understand the requirement of the study and/or comply with the
             study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Prince of Wales Hospital, Chinese University of Hong Kong</name>
      <address>
        <city>Shatin</city>
        <state>New Territories</state>
        <zip>SAR</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2010</study_first_submitted>
  <study_first_submitted_qc>January 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2010</study_first_posted>
  <last_update_submitted>August 9, 2016</last_update_submitted>
  <last_update_submitted_qc>August 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Chow Kai Ming</investigator_full_name>
    <investigator_title>Associate Consultant</investigator_title>
  </responsible_party>
  <keyword>peritoneal dialysis</keyword>
  <keyword>peritonitis</keyword>
  <keyword>CAPD</keyword>
  <keyword>end-stage renal disease</keyword>
  <keyword>peritonitis outcome and ultrafiltration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peritonitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dialysis Solutions</mesh_term>
    <mesh_term>Icodextrin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

